Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
Become a Member | Sign in
Home>News>This Article

Lab21 Announces Sale of South Carolina Operations

Published: Tuesday, April 23, 2013
Last Updated: Monday, April 22, 2013
Bookmark and Share
Company announces sale of its laboratory operations to Reedy Acquisitions Corp.

Lab21 Limited has announced the sale of its laboratory operations based in South Carolina to Reedy Acquisitions Corp, an entity formed by the existing local management and South Carolina based investors.

In addition to an immediate cash benefit for Lab21 Ltd, the sale will remove a loss-making business from the Lab21 Group.

The sale was completed at the end of 2012 and no financial details will be disclosed.

Susan Lowther, CFO of Lab21 Ltd said: “After three years of developing the clinical service business in South Carolina, the Group has taken the decision to sell the laboratory operations in Greenville and Columbia. This sale does not impact our core strategy to focus on personalized medicine and Lab21 will continue to focus on diagnostic content strategy opportunities within the US market.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Novacyt, Lab21 to Combine in Stock-For-Stock Transaction
On completing the transaction, Lab21 will become a 100% subsidiary of Novacyt, and the combined group will be rebranded.
Wednesday, May 28, 2014
Lab21, Quidel Expand International Distribution Agreement
Expanded agreement will see Lab21 distribute AnDiaTec’s Real-Time PCR Tests within the UK.
Tuesday, February 11, 2014
Lab21 and IntegraGen Partner
Lab21 Limited has entered into an agreement with IntegraGen to develop a microRNA assay for colorectal cancer designed to further improve patient outcomes.
Tuesday, March 05, 2013
Lab21 and IntegraGen Partner to Develop New Colorectal Cancer Diagnostic
Lab21 to develop a CE marked assay to detect expression levels of a microRNA biomarker.
Tuesday, February 26, 2013
BD and Lab21 Collaborate
Both Companies collaborate to develop new oncology assays on the BD MAX™ platform.
Tuesday, October 16, 2012
Clydesdale Bank £5 Million Funding to Support Lab21 International Growth
Lab21 is expected to deliver greater than 30% revenue growth in 2012.
Tuesday, July 10, 2012
Lab21 Partners with Major Pharmaceutical Company to Develop New Companion Diagnostic Assay
Agreement allows Lab21 to develop, manufacture and distribute a new companion diagnostic assay for the detection of specific mutations in colorectal cancer samples to select patients for the partner's therapeutic monoclonal antibody.
Tuesday, June 26, 2012
Lab21 Secures European and USA Patents for HCV Drug Resistance Genotyping
Company to expand its intellectual property portfolio in infectious disease testing.
Monday, May 21, 2012
Lab21 Unveils New Molecular Analysis Services at Greenville Site
The first assays in the test menu include a new Human Papillomavirus (HPV) High Risk and HPV 16 and 18 Genotyping Service.
Monday, May 14, 2012
Lab21 and ITOR Launch Clinical Genomics Center in USA
New Clinical Genomics Center will be located within the Greenville Hospital System (GHS) Memorial Medical Campus in Greenville, South Carolina.
Wednesday, March 07, 2012
Lab21 Acquires New Real Time PCR Technology
Company expects to launch diagnostic assays using PCR technology during first half of 2012.
Wednesday, January 25, 2012
Lab21 Acquires Molecular Diagnostics Company Myconostica
The acquisition of Myconostica expands Lab21’s growing proprietary diagnostic portfolio and will provide the Company’s first set of nucleic acid-based assays.
Tuesday, May 24, 2011
Lab21 to Support New US Cancer Institute With Molecular Diagnostic and Clinical Trial Services
Lab21 announces an agreement with ITOR to provide molecular diagnostic support services for new initiatives in drug development and advanced cancer patient care.
Wednesday, October 20, 2010
Lab21 Launches new Commercial Companion Diagnostic Service for HIV Tropism in UK
Company becomes the first commercial reference laboratory in the UK to provide a companion diagnostic service for the HIV drug, Celsentri.
Tuesday, August 31, 2010
Scientific News
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Biomedical Imaging at One-Thousandth the Cost
Mathematical modeling enables $100 depth sensor to approximate the measurements of a $100,000 piece of lab equipment.
Improving Outcomes for Lung Cancer and Diabetic Patients
Novel technologies have been developed with support from SBRI Healthcare funding.
New Way of Detecting Cancer
A new RNA test of blood platelets can be used to detect, classify and pinpoint the location of cancer by analysing a sample equivalent to one drop of blood.
Rapid, Portable Ebola Diagnostic
Scientists confirmed the efficiency of the novel Ebola detection method in field trials.
New, Better Test for Prostate Cancer
A study from Karolinska Institutet shows that a new test for prostate cancer is better at detecting aggressive cancer than PSA.
Blood Test Picks Out Prostate Cancer Drug Resistance
Scientists have developed a blood test that can identify key mutations driving resistance to a widely used prostate cancer drug, and identify in advance patients who will not respond to treatment.
Antibody Targets Key Cancer Marker
University of Wisconsin-Madison researchers have created a molecular structure that attaches to a molecule on highly aggressive brain cancer and causes tumors to light up in a scanning machine.
Key Piece of MRSA Vaccine Puzzle
New research funded by the Health Research Board and the Wellcome Trust has pinpointed immune cells that could be targeted by an MRSA vaccine.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos